TC BioPharm, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, has selected Excellos, a San Diego-based contract development and manufacturing organization (CDMO) spun out of San Diego Blood Bank, for its expanding U.S. clinical trial efforts. Excellos was chosen after an extensive review process due to their ability to navigate the complex regulatory impediments between the UK and U.S. which relate to the sourcing of donor material...